# Connective Tissue Disease-Associated ILD

## Overview

### Importance

| CTD | ILD Prevalence | Most Common ILD Pattern | Key Antibody | Unique Feature |
|-----|---------------|------------------------|--------------|----------------|
| Systemic sclerosis | 70–80% | NSIP (75%) | Anti-Scl-70 | Esophageal dilation on CT; Goh staging |
| PM/DM (antisynthetase) | 20–65% | NSIP, OP | Anti-Jo-1, anti-PL-7/12 | Mechanic's hands; relapsing course |
| PM/DM (anti-MDA5) | High | DAD, RP-ILD | Anti-MDA5 | Medical emergency; 30-50% mortality |
| Rheumatoid arthritis | 10–30% | UIP (40-60%) | RF, anti-CCP | Prognosis similar to IPF for UIP pattern |
| Sjogren syndrome | 10–20% | NSIP, LIP | Anti-Ro/La | LIP with thin-walled cysts is pathognomonic |
| SLE | 3–8% | NSIP | Anti-dsDNA | Shrinking lung syndrome; DAH |
| MCTD | 50–65% | NSIP | Anti-U1-RNP | May have concurrent PAH |

Interstitial lung disease is a leading cause of morbidity and mortality in patients with connective tissue diseases, and its presence fundamentally alters the prognosis and management approach. ILD may be the presenting manifestation of an underlying CTD, preceding systemic symptoms by months to years, a sequence that carries critical diagnostic implications. The prevalence of ILD varies substantially across different CTDs: systemic sclerosis demonstrates the highest prevalence at 70-80%, followed by mixed connective tissue disease at 50-65%, polymyositis and dermatomyositis at 20-65%, rheumatoid arthritis at 10-30%, Sjogren syndrome at 10-20%, and systemic lupus erythematosus at 3-8%. Given these frequencies, all patients presenting with ILD should be systematically screened for underlying CTD through targeted history, physical examination, and serologic testing.

### Interstitial Pneumonia with Autoimmune Features (IPAF)

The ERS/ATS 2015 research classification introduced the concept of interstitial pneumonia with autoimmune features (IPAF) to describe patients with ILD who exhibit autoimmune features but do not meet the diagnostic criteria for any defined CTD. The classification requires features from at least two of three domains: the clinical domain (specific extrathoracic features such as Raynaud phenomenon, arthritis, or skin findings), the serologic domain (specific autoantibodies), and the morphologic domain (HRCT patterns, histologic features, or BAL findings suggestive of autoimmune-associated disease). IPAF is not a diagnosis but rather a research classification, and its prognostic implications are still being defined. Patients with IPAF may evolve into a classifiable CTD over time and require longitudinal follow-up.

## Systemic Sclerosis-Associated ILD (SSc-ILD)

### Epidemiology and Risk Factors

ILD is present on HRCT in 70-80% of systemic sclerosis patients, though clinically significant disease requiring treatment consideration affects 25-30%. Diffuse cutaneous SSc confers a higher risk of ILD than limited cutaneous SSc. Anti-Scl-70 (anti-topoisomerase I) antibodies are strongly associated with ILD and are present in approximately 40% of SSc-ILD patients, while anti-centromere antibodies are protective against ILD but associated instead with pulmonary arterial hypertension. Additional risk factors for progression include male sex, Black race, early disease within the first 5 years, baseline FVC below 70% predicted, and extensive HRCT involvement defined as 20% or more of the lung parenchyma.

### Radiologic and Histologic Pattern

NSIP is the predominant histologic and radiologic pattern in SSc-ILD, accounting for approximately 75% of cases, while UIP pattern is found in approximately 15%. HRCT findings characteristically include ground glass opacity with fine reticulation in a basal-predominant distribution, and esophageal dilation visible on CT serves as a helpful diagnostic clue pointing toward systemic sclerosis. The Goh staging system classifies disease extent for treatment decision-making: involvement of 20% or more on HRCT constitutes extensive disease, while for indeterminate extent, an FVC below 70% predicted is used as a surrogate marker.

### Management

Mycophenolate mofetil (MMF) has emerged as first-line therapy for SSc-ILD. The Scleroderma Lung Study II (SLS II) demonstrated that MMF was non-inferior to cyclophosphamide for FVC improvement at 2 years, with significantly better tolerability, at a dose of 1.5 g twice daily. Cyclophosphamide, validated in the SLS I trial with a modest FVC improvement of 2.5% over placebo at 12 months, has been largely replaced by MMF as first-line treatment, though benefits waned after cessation. Nintedanib is approved for SSc-ILD based on the SENSCIS trial, which demonstrated a reduction in annual FVC decline by 44 mL per year representing a 41% relative reduction; notably, 75% of trial participants were receiving background MMF, establishing that nintedanib can be combined with immunosuppression. Tocilizumab (anti-IL-6 receptor) received FDA approval for SSc-ILD based on the focuSSced trial, which showed a trend toward FVC preservation that reached significance in exploratory analysis, administered at 162 mg subcutaneously weekly. Rituximab is increasingly used based on retrospective data and the RECITAL trial, which demonstrated non-inferiority to cyclophosphamide for CTD-ILD including SSc-ILD. Autologous hematopoietic stem cell transplantation (HSCT), evaluated in the ASTIS, SCOT, and ASSIST trials, has demonstrated superiority over cyclophosphamide for event-free survival in early severe diffuse cutaneous SSc, but is reserved for severe progressive disease given treatment-related mortality of 3-10%. Lung transplantation should be considered for refractory progressive disease, with SSc-specific concerns including GERD, esophageal dysmotility, and skin tightening.

<image>A treatment algorithm for SSc-ILD management. Start with newly diagnosed SSc-ILD. First assessment: Goh staging (limited < 20% HRCT extent AND FVC >= 70% vs. extensive >= 20% or FVC < 70%). For limited/stable disease: monitor with PFTs q3-6 months + HRCT annually. For extensive or progressive disease: first-line MMF 1.5g BID. If progressive despite MMF (FVC decline >= 5-10%): add nintedanib 150 mg BID to MMF. If still progressive: consider rituximab, tocilizumab, or cyclophosphamide. For rapidly progressive early dcSSc: consider autologous HSCT. Show lung transplant referral criteria. Include monitoring schedule with PFT frequency at each stage.</image>

## Rheumatoid Arthritis-Associated ILD (RA-ILD)

### Epidemiology

Clinically significant ILD affects 10-30% of RA patients, while subclinical ILD is detectable on HRCT in up to 60%. ILD is the second leading cause of death in RA after cardiovascular disease, underscoring its clinical importance. Risk factors include male sex, older age, smoking, high-titer rheumatoid factor and anti-CCP antibodies, and the presence of rheumatoid nodules. Drug-induced ILD must be carefully excluded, as methotrexate, leflunomide, TNF inhibitors, and JAK inhibitors can all cause lung toxicity.

### Patterns

The UIP pattern is the most common radiologic and histologic pattern in RA-ILD, accounting for 40-60% of cases, and carries a prognosis similar to IPF. NSIP pattern occurs in 15-25% and confers a better prognosis. Less common patterns include organizing pneumonia, LIP, and DIP. Airway disease manifesting as bronchiolitis and bronchiectasis is very common in RA but represents a separate entity from ILD.

### Management

No randomized controlled trials have been conducted specifically in RA-ILD. For UIP-pattern RA-ILD, antifibrotic therapy is increasingly used, with nintedanib or pirfenidone employed off-label. For NSIP or inflammatory-pattern disease, immunosuppression with MMF, azathioprine, or rituximab is the approach of choice. Progressive RA-ILD meeting PPF criteria is eligible for nintedanib therapy based on the INBUILD trial, which included RA-ILD patients. An important clinical consideration is that methotrexate need not be reflexively discontinued in RA-ILD; large observational data, including the VARA study, suggest that methotrexate may actually be protective against RA-ILD development. True drug-induced ILD from methotrexate is rare and should be carefully distinguished from RA-ILD progression.

## Inflammatory Myopathy-Associated ILD (PM/DM-ILD)

### Myositis-Specific Antibodies and ILD Risk

The identification of myositis-specific antibodies has transformed the approach to inflammatory myopathy-associated ILD, as different antibodies predict distinct clinical phenotypes, ILD patterns, and prognoses. Anti-MDA5 (anti-CADM-140) is associated with rapidly progressive ILD in the setting of clinically amyopathic dermatomyositis (CADM), carrying a very high mortality of 30-50%, and may present without any myositis whatsoever, with an Asian predominance. Anti-Jo-1, the most common antisynthetase antibody, is associated with ILD in 70-80% of patients, moderately progressive disease, and generally good response to immunosuppression. Anti-PL-7 and anti-PL-12 are associated with an ILD-predominant antisynthetase phenotype in which myositis may be minimal. Anti-Mi-2 is associated with classic dermatomyositis rash but carries a low risk of ILD. Anti-NXP2 and anti-TIF1-gamma are associated with malignancy and variable ILD risk.

### Antisynthetase Syndrome

Antisynthetase syndrome comprises the triad of ILD, myositis, and arthritis, frequently accompanied by mechanic's hands, Raynaud phenomenon, and fever. NSIP and organizing pneumonia are the most common ILD patterns encountered. The disease generally responds well to immunosuppression, though a chronic relapsing course is common. Treatment consists of corticosteroids, typically prednisone at 1 mg/kg, combined with a steroid-sparing agent such as MMF, azathioprine, or tacrolimus.

### Anti-MDA5 Rapidly Progressive ILD

Anti-MDA5 rapidly progressive ILD represents a medical emergency with mortality rates of 30-50% despite aggressive treatment. HRCT demonstrates rapidly progressive ground glass opacity and consolidation. Treatment requires triple immunosuppression combining high-dose corticosteroids with a calcineurin inhibitor (tacrolimus or cyclosporine) and either cyclophosphamide or rituximab, with plasma exchange considered in refractory cases. JAK inhibitors, particularly tofacitinib, are emerging as promising agents based on Japanese cohort studies showing efficacy in anti-MDA5 RP-ILD. Serum ferritin levels, often exceeding 1000 ng/mL, correlate with disease severity and prognosis, and serial monitoring is useful for guiding treatment response.

<image>A comprehensive table of myositis-specific antibodies and their clinical associations relevant to ILD. Create a visual matrix with antibody names as rows (anti-Jo-1, anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, anti-MDA5, anti-Mi-2, anti-NXP2, anti-TIF1-gamma, anti-SRP) and clinical features as columns (ILD risk, ILD pattern, ILD severity, myositis severity, skin involvement, malignancy risk, prognosis). Use color coding: red for high risk/poor prognosis, yellow for moderate, green for low risk/good prognosis. Highlight anti-MDA5 row with a red border indicating medical emergency. Include small HRCT pattern icons (NSIP, OP, DAD) in the ILD pattern column.</image>

## Other CTD-Associated ILD

### Sjogren Syndrome

ILD occurs in 10-20% of Sjogren syndrome patients, with NSIP and LIP being the most common patterns. LIP is characterized by thin-walled cysts with ground glass opacity and is pathognomonic for Sjogren syndrome when present. Follicular bronchiolitis represents another characteristic pulmonary pattern. Lymphoma risk necessitates monitoring for transformation of LIP to lymphoma, particularly MALT lymphoma.

### Systemic Lupus Erythematosus (SLE)

Chronic ILD is uncommon in SLE, affecting only 3-8% of patients, with NSIP being the predominant pattern when present. Acute lupus pneumonitis presents with bilateral infiltrates and fever, and differentiation from infection is critical. Shrinking lung syndrome is a distinctive entity characterized by progressive dyspnea with small lung volumes and elevated diaphragms, resulting from diaphragmatic dysfunction rather than parenchymal disease, and it responds to immunosuppression. Diffuse alveolar hemorrhage is a life-threatening complication caused by pulmonary capillaritis and treated with pulse methylprednisolone, cyclophosphamide, and plasma exchange.

### Mixed Connective Tissue Disease (MCTD)

ILD occurs in 50-65% of MCTD patients, with NSIP being the most common pattern. The anti-U1-RNP antibody defines MCTD. Pulmonary arterial hypertension may coexist with ILD. Treatment follows principles similar to those used for SSc-ILD.

## General Management Principles for CTD-ILD

### Monitoring

Disease monitoring requires pulmonary function tests with spirometry and DLCO every 3-6 months during active disease and every 6-12 months when stable. HRCT should be obtained at baseline and as clinically indicated while avoiding excessive radiation. Coordinated care with rheumatology for systemic disease management is essential.

### Treatment Decision Framework

The treatment decision framework for CTD-ILD is guided by the predominant disease pattern. Inflammatory-predominant disease, characterized by ground glass opacity, cellular NSIP, or organizing pneumonia, is treated with immunosuppression combining corticosteroids with a steroid-sparing agent. Fibrotic-predominant disease, characterized by reticulation, honeycombing, or traction bronchiectasis, is treated with antifibrotic therapy with or without immunosuppression. Disease meeting progressive pulmonary fibrosis (PPF) criteria is eligible for nintedanib based on the INBUILD trial. The RECITAL trial established rituximab as non-inferior to cyclophosphamide as first-line therapy for severe CTD-ILD, including SSc, myositis, and MCTD.

## Key Clinical Pearls

- All patients with ILD should be screened for underlying CTD with targeted history (Raynaud's, arthritis, skin changes, dysphagia, dry eyes/mouth, muscle weakness), physical exam, and serologies (ANA, RF, anti-CCP, myositis panel, Scl-70)
- Anti-MDA5 rapidly progressive ILD is a medical emergency requiring urgent triple immunosuppression; ferritin levels correlate with severity and can guide treatment response
- In SSc-ILD, mycophenolate is first-line (SLS II), and nintedanib can be added for progressive disease (SENSCIS); they can be used concomitantly
- Methotrexate does NOT need to be reflexively stopped in RA-ILD; observational data suggests it may be protective, and drug-induced ILD from MTX is rare (distinguish from RA-ILD progression)
- IPAF is a research classification for ILD with autoimmune features not meeting defined CTD criteria; it may evolve into a classifiable CTD over time and requires longitudinal follow-up

## References
1. Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708-719.
2. Distler O, Highland KB, Gahlemann M, et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019;380(26):2518-2528. (SENSCIS)
3. Saunders P, Tsipouri V, Keir GJ, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): a randomised, controlled, open-label trial. Lancet Respir Med. 2024;12(2):131-141.
4. Fischer A, Antoniou KM, Brown KK, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46(4):976-987.
5. Gupta R, Vummidi D, Engel A, et al. Anti-MDA5 dermatomyositis-associated rapidly progressive interstitial lung disease: a narrative review. Rheumatology. 2023;62(7):2279-2290.